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Transition metal catalysis in the mitochondria
of living cells
Marı́a Tomás-Gamasa1, Miguel Martı́nez-Calvo1, José R. Couceiro1 & José L. Mascareñas1
The development of transition metal catalysts capable of promoting non-natural
transformations within living cells can open significant new avenues in chemical and cell
biology. Unfortunately, the complexity of the cell makes it extremely difficult to translate
standard organometallic chemistry to living environments. Therefore, progress in this field
has been very slow, and many challenges, including the possibility of localizing active metal
catalysts into specific subcellular sites or organelles, remain to be addressed. Herein, we
report a designed ruthenium complex that accumulates preferentially inside the mitochondria
of mammalian cells, while keeping its ability to react with exogenous substrates in a
bioorthogonal way. Importantly, we show that the subcellular catalytic activity can be used
for the confined release of fluorophores, and even allows selective functional alterations in
the mitochondria by the localized transformation of inert precursors into uncouplers of the
membrane potential.
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T
he functioning of the cell depends on the regulated action
of thousands of different enzymes that have evolved to
catalyse a wide range of chemical reactions. In many cases,
the correct working of these enzymes requires an appropriate
localization in specific organelles and/or subcellular sites1. This
is the case, for instance, for mitochondrial enzymes, which need
to be associated with different mitochondrial components in
order to exert their critical role in cellular respiration2–4.
Given the biological relevance of this type of intracellular
localization, it is reasonable to envision that installing artificial
enzymes with non-natural functions in designed cellular
compartments might unveil new opportunities for probing and
manipulating cell biology. While recent years have witnessed
notable advances in the implementation of evolved enzymes
capable of achieving in vitro non-natural transformations5–7,
including artificial metalloenzymes8–12, engineering of this type
of systems in in vivo settings is far from obvious.
An alternative and highly appealing way to generate localized,
abiotic catalytic activities inside cells could be based on the
targeted subcellular delivery of transition metal catalysts. However,
achieving catalytic organometallic reactions inside living cells
is not trivial, and many problems associated to the activity,
stability, aqueous and biological compatibility, orthogonality,
and cell entrance can be envisioned. The living cell is a very
complex, compartmentalized and dynamic entity, with a very high
concentration of biomolecules, ions and other structures in
complex equilibrium, and can therefore be considered as a very
stringent reaction medium.
Despite all these potential complications, recent data suggest
that certain transition metal derivatives can promote intracellular
reactions through typical organometallic mechanisms.
Particularly relevant in this context has been the pioneering
work by Meggers and coworkers, who demonstrated that
discrete organoruthenium complexes could be used for the
in cellulo uncaging of allylcarbamate protected (alloc) amines13,14.
Our laboratory has reported that this type of catalysts can be
employed for the uncaging of DNA binders15. Importantly, while
these results point to intracellular reactions, a recent publication
by Waymouth and Wender suggests that, at least in 4T1 cells,
these Ru complexes are readily washed out with PBS, and raises
doubts on the intracellularity of the metal catalysis16.
Other important contributions in the area of in cellulo metal
catalysis deal with the use of palladium complexes, albeit
success in these transformations seems to require the use of
heterogeneous nanostructured palladium species, and in most
of the cases, in cellulo imaging of the catalytic responses has been
analysed after fixation of the cells17–19.
All these data confirm that achieving organometallic catalytic
reactions of exogenous substrates within living cells is certainly
tricky20–25. While the field is in its infancy and further progress
requires the development of new biocompatible transformations,
there is an urgent need to make operative catalysts that are well
retained inside cells and ensure intracellular activities. In
addition, there are many other questions that remain to be
addressed. Is it possible to concentrate the catalyst within a
specific organelle/environment while keeping its activity, and
without generating toxicity? Would it be possible to visualize the
catalyst within the cell and the organelles? Is it possible to use the
confined catalyst to generate a differentiated biological effect?
Could this localization provide a functional advantage?
In the present manuscript, we provide some answers to these
questions by describing a designed ruthenium conjugate that is
capable of accumulating in the mitochondria of living cells
and promoting a localized uncaging of alloc/allyl protected
exogenous substrates, reaction that operates through typical
pi-allyl-mediated mechanisms (Fig. 1a,b). In addition to
confirming the intracellular performance of the catalyst, this
work represents the first demonstration that it is possible to
generate abiotic, bioorthogonal catalytic power in subcellular
compartments of living cells.
Results
Mitochondria targeting. Mitochondria are complex organelles
found in almost all eukaryotic cells that play vital roles in
the regulation of cellular function and survival4,26. Therefore,
along the last years, there have been many efforts to engineer
cell permeable vectors capable of targeting this organelle27–29.
A particularly successful delivery platform is based on the use
of triphenylphosphonium (TPP) cations, which exhibit a single
positive charge resonance-stabilized over three phenyl groups
and a large hydrophobic surface area. It is known that the
accumulation of these type of lipophilic cationic compounds is
driven by the membrane potential across the mitochondrial inner
membrane30. TPP cations can be therefore taken up by the
mitochondrial matrix, where they are freely soluble or adsorbed
on the leaflet of the inner membrane depending on the
hydrophobicity of the cargo30,31.
Even though the functional complexity of mitochondria suggests
that it might be incompatible with organometallic chemistry, we
were intrigued by the possibility of accumulating active transition
metal complexes in this organelle using a TPP delivery vector.
Following recent work on the use of discrete ruthenium catalysts to
promote an orthogonal removal of alloc protecting groups13–15, we
decided to explore the use of 2-quinolinecarboxylate (QC) ligand
as platform for the introduction of the required phosphonium-
targeting groups14,32. Towards this end, we prepared the complex
RuL1 (Fig. 2), in which the metallic centre contains a modified QC
ligand linked to a TPP group through a relatively hydrophobic
alkyl chain. This new structure is a lipophilic dication that might
have an intrinsic preference for accumulation in the mitochondria.
The hydrophobic linker should counterbalance the Born energy of
the two charges, and favour the membrane crossing processes.





















Figure 1 | Aim of the present study. (a) Transition metal pi-allyl chemistry.
(b) Preferential accumulation of the metal catalyst in the mitochondria owing to
the targeting group P. M , metal complex; P , mitochondria-targeting group.
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2-carboxylic acid (1)33, via the sequence of steps shown in the
Fig. 2, which involves the preparation of the ligand and its
complexation to the ruthenium precursor [RuCp(CH3CN)3]PF6
(see Supplementary Methods and Supplementary Figs 1–4
for details).
For comparison purposes, we also made the parent complex
Ru1, which lacks the TPP-containing appendage. Although
previous studies had indicated that the catalytic activity of
these ruthenium derivatives is favoured by the presence of
electron donor groups in the quinoline, in the context of our
research these derivatives, which demand a more elaborated
synthesis, are not required14.
In vitro and cellular reactivity. To evaluate the catalytic
capabilities of these complexes, we selected the transformation of
the bis-allyloxycarbonyl-protected rhodamine (Rho-Alloc) into
its corresponding free-amine derivative (Rho), reaction that can
be monitored by fluorescence (Fig. 3a)13–15.
Before testing the reactivity in living cells, we analysed the
in vitro performance of both metal complexes using biologically
relevant reaction media. The experiments were carried out using
5% of the ruthenium complex either in water, PBS (pH 7.2) or
HeLa cell lysates, and a concentration of Rho-alloc of 100 mM. As
it can be observed in Fig. 3a,b, the reaction rates and conversions
depend on the reaction conditions. Both complexes presented
activity, although RuL1 was much more active than complex Ru1
in all the media studied, even in cell lysates. In relative terms, the
activity in water and PBS was always higher for both catalysts,
with a substantial decrease in cell lysates. However, RuL1 led to a
lower decrease than Ru1. Nevertheless, in both cases, rate and
turnover were lower than those previously described for Ru1
using other substrates and reaction media, in part because of
solubility problems of the probe (Supplementary Table 1)14.
Even though the reactivity was poor in the above conditions,
we examined their performance in living cells using human
cervical cancer cells (HeLa cells). Since our objective is the
installation of artificial catalysts in a subcellular site, we carried
out the experiments in an inverse way to that used in previous
studies, in which the substrate was added to the cells before the
catalyst13–15. To avoid misinterpretations arising from potential
toxic effects of the metal complexes, we first analysed the cell
viability. Gratifyingly, using the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay34, we were glad to
observe that both Ru1 and RuL1 are quite innocuous, and only
promote a decrease in the viability at concentrations 4100mM
(30% decrease) and after 24 h of incubation (after 2 h we did not
detect any toxicity, Supplementary Fig. 5).
Considering the previously mentioned recent report suggesting
that ruthenium catalysts such as Ru1 are readily washed out
with PBS in cellular settings16, we performed parallel experiments
to compare the catalytic performances of Ru1 and RuL1
(Fig. 3; Supplementary Fig. 6). Therefore, cultured cells were
treated with either ruthenium complex Ru1 or RuL1 (25 mM) for
15 min in fresh DMEM-FBS (DMEM supplemented with 5% of
fetal bovine serum), followed by washing for 20 min with PBS16.
The resulting cells were then incubated with Rho-alloc (100 mM)
in fresh DMEM-FBS for 30 min and washed for 4 min with PBS.
In consonance with that observed by Waymouth and Wender16,
the green staining inside cells treated with Ru1 was very
weak (Fig. 3d, panel B). In contrast, and importantly, we
observed an intense green fluorescence in cells treated with
RuL1 (Fig. 3d, panel C). This suggests that the presence of the
TPP appendage allows a much better intracellular retention of
the complex (RuL1). It is important to note that control
experiments with Ru1 revealed that if the cells are washed with
DMEM-FBS instead of PBS there is clear intracellular
fluorescence (Supplementary Fig. 7).
Interestingly, when the above uncaging of Rho-alloc with
RuL1 (100 mM) was carried out in cells previously treated
with the mitochondrial dye tetramethylrhodamine ethyl ester
(TMRE, 100mM)35, we observed that the intracellular green
staining co-localizes, at least in part, with the TMRE dye (Fig. 3e,
panels D–F). This was better appreciated by comparing this
costaining with that obtained in cells treated with Ru1, which
promoted a less intense and diffuse fluorescence signal
extended across the cytoplasm (Supplementary Fig. 7). Control
experiments in the absence of ruthenium complexes confirmed
that there is not an observable intracellular fluorescence even
after several hours of incubation with the caged fluorophore.
These results confirmed that the structure of the catalyst
influences the reactivity profile, and that RuL1 generates a
more intense fluorescence inside cells, mainly localized in the
mitochondria surroundings. Inductively coupled plasma mass
spectrometry (ICP-MS) analysis of cells incubated with equal
concentrations of both complexes further confirmed that RuL1 is
better retained by cells, and more concentrated in the











































Figure 2 | Ruthenium complexes Ru1 and RuL1. Synthesis of RuL1: (a) 1 (1.0 equiv.), allyl bromide (1.6 equiv.), KHCO3 (1.7 equiv.), DMF, 12 h, 50 C, 75%;
(b) 3-N-methyl-propanol (5.0 equiv.), DMSO, 1 h, 100 C, 87%; (c) (3-carboxypropyl)triphenylphosphonium bromide (1.0 equiv.), EDC (2.5 equiv.), DMAP
(2.0 equiv.), 12 h, room temperature, 30%; (d) [RuCp(CH3CN)3]PF6 (1.0 equiv.), DCM, 12 h, room temperature, 65%. DCM, dichloromethane; DMAP,
4-dimethylaminopyridine; DMF, N,N-dimethylformamide; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
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Figure 3 | Uncaging experiments of Rho-alloc with Ru1 and RuL1. (a) Schematic representation of the uncaging reaction of Rho-alloc. (b,c) Ru1- (b) and
RuL1-(c) catalysed uncaging of Rho-alloc under biologically relevant conditions. Reaction conditions: Rho-alloc (500mM, 1 equiv.), ruthenium complex
(5mM, 0.05 equiv.) in 120ml solution of either HeLa cells lysates, PBS (þ 5 mM of glutathione, 10 equiv.) or water (þ 5 mM of glutathione, 10 equiv.).
(d) Micrographs showing the fluorescence of the product (Rho) in cells treated with the ruthenium complexes (25mM) for 15 min (except in case A), washed
for 20 min with PBS; treated with Rho-alloc (100mM) for 30 min and washed again for 4 min with PBS. (A) control experiment, not ruthenium complex added;
(B) results with complex Ru1; (C) results with complex RuL1. (e) Fluorescent micrographies of HeLa cells after RuL1-catalysed uncaging of Rho-alloc.
(D) Mitochondrial labelling with TMRE (red channel)35. (E) Fluorescence resulting from the RuL1 promoted reaction (green channel) and (F) merging
of D and E. Reaction conditions: cells were incubated with RuL1 (50mM) and TMRE (100 nM) for 30 min, followed by double washing with DMEM-FBS and
incubation with Rho-alloc (100mM) for 30 min. Scale bar, 12.5mm. Error bars represent the standard deviation of measurements in three different samples.
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To gain more information on the system, and to track the
intracellular presence of the metal complexes, we pursued the
development of derivatives equipped with fluorescent labels.
Previous approaches to make fluorescent TPP cations have
been based on the attachment of external fluorophores36,37.
However, this strategy introduces important structural changes
in the probe. We envisioned that an alternative based on the
replacement of one of the phenyl rings of the phosphonium
group by a pyrene derivative might allow fluorescent monitoring
while keeping the required hydrophobicity/charge balance of the
targeting vector. Thus, we prepared the pyrene-phosphonium
complex RuL2, as well as the analogue RuL3 that lacks the
phosphonium group and could therefore be used as reference
(Fig. 4a; see the Supplementary Methods for synthetic details).
The ultraviolet–visible spectra of RuL2 and RuL3 showed a set of
bands of the QC unit centred at ca. 275 nm, whereas at lower
energy there is the typical set of bands corresponding to the
pyrene ring with a lmax at 345 nm. The fluorescence spectra
displayed maxima at 385 and 390 nm for RuL2 and RuL3,
respectively (Supplementary Fig. 8).
Gratifyingly, the addition of TMRE (100 nM) and RuL2
(50 mM) to HeLa cells, followed by double washing with
DMEM-FBS elicited a clear intracellular blue fluorescence after
5 min of incubation (Fig. 4b, panel B), staining that presents an
excellent overlay (Mander’s coefficient B90%)38 with the marker
TMRE (Fig. 4b, panel C). Subsequent experiments revealed that a
final catalyst concentration as low as 10 mM is even enough for
the uptake and imaging. Importantly, cells treated with the
conjugate RuL3, a control complex lacking the phosphonium
moiety, showed a different staining pattern (Fig. 4c, panel B), as
can be observed in the TMRE co-localization picture (Fig. 4c,
panel C), with the fluorescence preferentially located in the
perinuclear region.
Importantly, ICP experiments of cells incubated with the same
concentrations of both complexes corroborated that the
phosphonium-pyrene derivative RuL2 was better retained than
RuL3. Moreover, ICP analysis of the ruthenium content in
isolated mitochondria of the cells, revealed a much higher
proportion in the cells treated with RuL2. Therefore, the presence
of the pyrene moiety in RuL2 increased its cellular and
mitochondrial retention with respect to the triphenylphospho-
nium analogue RuL1 (Supplementary Table 2), which suggests
that the phosphonium-pyrene unit is an excellent mitochondrial
tagging fluorescent group, and might be used for other
applications39.
While the appearance and morphology of the cells suggested
that both ruthenium complexes are innocuous, this was further
confirmed with MTT cytotoxicity assays. As in the case of Ru1
and RuL1, both pyrene-ruthenium derivatives induced only a
slight decrease of cell viability after 24 h of incubation at high
concentrations (Supplementary Fig. 5).
Intracellular reactivity of the pyrene-ruthenium derivatives.
The previous experiments confirmed that the complex RuL2 has
excellent cell membrane permeability, can be readily taken up by
the cell mitochondria, is firmly retained inside the cell (even after
a 20 min PBS washing, Supplementary Fig. 6) and does not
compromise cell survival. A key question now was finding out
whether the mitochondria-confined complex is catalytically
active. Remarkably, the addition of Rho-alloc (100 mM) to cells
that had been previously treated with TMRE (100 nM) and
either ruthenium complex (50 mM), and thoroughly washed with
DMEM-FBS, led to intracellular green staining patterns.
Interestingly, while the green emission of the reaction product
(Rho) observed in cells treated with RuL2 matched almost
perfectly the red fluorescence of the TMRE dye as well as the blue
fluorescence coming from RuL2 (Fig. 4b, panels E and F,
respectively and Fig. 5), in cells incubated with RuL3 the green
fluorescence of Rho showed a much poorer correlation with
the mitochondrial dye TMRE (Fig. 4c, panel E). Particularly
illustrative is the comparison between the overlays obtained from
RuL2 and RuL3, represented in panels E (Fig. 4b,c, respectively).
Also importantly, similar catalytic results, that could be fully
replicated, were observed when the same experiments were
carried out in adenocarcinomic human alveolar basal epithelial
cells (A549 cells, Supplementary Fig. 9).
Using the Mander’s method, the co-localization data were
quantified and the results are displayed in Fig. 5 (ref. 40). As can
be deduced from the values obtained, there is a notable difference
between both catalysts. In cells incubated with RuL2, there is high
co-localization of the mitochondrial marker TMRE with both the
reaction product Rho and the catalyst, with values of 73% and
88%, respectively (red signal overlapping green and blue);
however, the values drop to B35% in cells incubated with
RuL3, which are similar to those observed for cells incubated
with Ru1.
The above data are fully consistent with a pi-allyl-mediated
organometallic reaction occurring in the mitochondria of living
cells, reaction that generates products in a highly localized
manner. Curiously, in vitro catalytic assays using cell lysates as
reaction medium revealed that RuL2 (5 mol%) had a very poor
performance, as we only observed a 0.2% of conversion after 4 h
at 37 C (RuL3 leads to a 12.4% conversion in the same
conditions; Supplementary Table 1). Although this low activity is
in great part due to solubility or aggregation problems, it comes
to indicate that in vitro results do not necessarily correlate with
the reactivity profile in the environment of living cells and/or
specific organelles.
In consonance with the proposed mechanism of mitochondrial
localization based on the membrane potential, we observed
that adding a depolarizing agent-like carbonylcyanide p-triflour-
omethoxy-phenylhydrazone (20 nM)41 to cells pretreated with
RuL2 (50 mM) promotes a diffuse blue staining no longer
associated to the mitochondria. As expected, addition of the
pro-fluorescent probe Rho-alloc led to an accumulation of green
fluorescence throughout the cytoplasm rather than in the
mitochondria (Supplementary Fig. 10).
Activation of a mitochondrial membrane-uncoupler agent.
While the above experiments demonstrated that the preferential
accumulation of metal complex RuL2 in mitochondria promoted
a confined catalytic response, it remained to be shown whether
such subcellular reactivity could provide a functional advantage.
Towards this end, we paid attention to the possibility of a
localized generation of 2,4-dinitrophenol (DNP), a protonophore
known to decrease the mitochondrial membrane potential and
switch off the ATP production (Fig. 6a)42,43. Importantly,
control experiments confirmed that the allyl-caged derivative
DNP-allyl failed to elicit any observable biological effect in the
mitochondria, even at relatively high concentrations (500 mM).
However, treatment of HeLa cells with 500 mM of the phenol-free
form (DNP) produced a depolarization in the mitochondria, as
can be deduced from the change in the fluorescence staining
induced by the TMRE and its decrease in intensity (Fig. 6b,
panel D)44. TMRE is a cell permeable, positively charged,
red–orange dye that readily accumulates in active mitochondria.
Depolarized or inactive mitochondria have decreased membrane
potential and fail to sequester TMRE, which therefore generates a
decreased intensity and a much less defined red staining
(Supplementary Fig. 11).
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Figure 4 | Reactivity of ruthenium complexes RuL2 and RuL3 in HeLa cells. (a) Structure of the ruthenium complexes RuL2 and RuL3. (b) Subcellular
localization and catalytic activity of RuL2 and (c) RuL3. (A) Mitochondrial labelling with TMRE (red), (B) emission of the metal complex (blue),
(C) merging of A and B, (D) Rho fluorescence in cells preincubated with the ruthenium catalysts after addition of Rho-alloc, (E) merging of A and D, and
(F) merging of B and D. Reaction conditions: cells were incubated with the catalyst (50 mM) and TMRE (100 nM) for 30 min, followed by two washings with
DMEM-FBS and treatment with Rho-alloc (100mM) for 30 min. Scale bar, 12.5mm.
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Using TMRE as indicator, we found that neither metal
complex RuL2 nor RuL3 produced major damages in the
mitochondria potential, even after 24 h (Fig. 6b, panels A and B).
However, the addition of DNP-allyl (150 mM) to the cells
previously treated with RuL2, produced a rapid damage in
the mitochondrial membrane potential, as deduced from the
considerable decrease in the TMRE fluorescence observed after
30 min (Fig. 6b, panel C). This effect must arise from the
subcellular confined release of the active uncoupler DNP, because
addition of the same amount of substrate to cells pretreated with
RuL3, which lacks the phosphonium-targeting moiety, produced
a very weak depolarization effect (Fig. 6b, panel E). This result has
been reproduced not only in HeLa but also in other mammalian
cells such as Vero (Supplementary Fig. 12). Therefore, the
mitochondria-confined catalyst led to a much more efficient and
rapid response, most probably because of an intense, confined
and probably amplified release of the damaging agent (Fig. 6c).
Also important, while the generation of a reproducible
damaging effect with the active drug (DNP) required the use of
concentrations 4500mM, cells pretreated with RuL2 were able to
generate reproducible depolarization effects employing only
150mM of the DNP-allyl precursor (Fig. 6d), which suggests
that the confined catalyst not only enables the use of an inert
prodrug but also allows to decrease the dosage.
In conclusion, we have described the first non-toxic, transition
metal complex that is capable to promote an abiotic organometallic
catalytic transformation of designed exogenous substrates within
the mitochondria of living cells. Appropriate fluorescent labelling
allows tracking the intracellular localization of the metal
complexes, localization that depends on the structure of the metal
ligands. The use of the pyrene-phosphonium-targeting group and a
hydrophobic linker allows for a preferential mitochondrial
accumulation of the ruthenium complex and ensures its
intracellular retention. Importantly, we have also demonstrated
that the confined installation of the metal catalyst can be used to
obtain functional advantages, such as a smooth and rapid
ruthenium-dependent depolarization of the mitochondria.
These studies, by enabling catalytic functions that are absent in
nature, open new avenues and opportunities in the use of typical
transition metal catalysis for the selective manipulation of living
systems.
Methods
General. Chemical synthesis procedures, detailed protocols and characterization of
all the compounds are included in the Supplementary Methods section. For NMR
and high-resolution electrospray ionisation mass spectrometry (HR-ESI-MS)/
MALDI-TOF analysis of the compounds in this article, see Supplementary
Figs 13–25.
Synthesis of L1. Allyl 4-[(3-hydroxypropyl)(methyl)amino]quinoline-2-carbox-
ylate was synthesized from precursor 4-bromoquinoline-2-carboxylic acid (1)33.
(3-Carboxypropyl)triphenylphosphonium bromide (46.0 mg, 0.11 mmol)
was dissolved in N,N-dimethylformamide (DMF) (1 ml). 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (52.0 mg, 0.27 mmol), allyl 4-[(3-
hydroxypropyl)(methyl)amino]quinoline-2-carboxylate (32.0 mg, 0.11 mmol) and
4-dimethylaminopyridine (26.0 mg, 0.22 mmol) were subsequently added to the
solution. The reaction mixture was left stirring overnight and the solvent was
removed under reduced pressure. The crude was purified by flash chromatography



























Figure 5 | Co-localization studies of the ruthenium catalysts in HeLa cells. (a) Co-localization coefficients (Mander’s coefficients, M1) performed on
dual-colour images from fluorescent microscopy experiments represented in Fig. 4. (b) Bars representation of the Mander’s coefficients. Yellow bar:
fraction of TMRE overlapping green signal of the reaction product Rho; magenta bar: fraction of TMRE overlapping blue signal of the catalyst. Error bars
represent the standard deviation of measurements in three different samples.
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Figure 6 | Activation of DNP-allyl inside HeLa cells. (a) Schematic representation of the uncaging reaction of DNP-allyl with RuL2 and RuL3.
(b) Fluorescence micrographs of the mitochondrial staining with TMRE (100 nM) of: (A) cells incubated with RuL2 (50 mM), (B) cells incubated with RuL3
(50mM), (C) cells treated with DNP-allyl (150mM) after incubation with RuL2, (D) cells treated with DNP (500mM) and (E) cells treated with DNP-allyl
(150mM) after incubation with RuL3. (c) Quantification of the fluorescence of the micrographs from section (b) showing the normalized decrease of the
TMRE fluorescence. (d) Influence of the concentration of DNP/DNP-allyl on the mitochondrial depolarization of HeLa cells. Scale bar, 12.5 mm. Error bars
represent the standard deviation of measurements in three different samples.
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Synthesis of the ruthenium complex RuL1. To a 10 mM solution of ligand L1
(1.0 equiv.) in anhydrous dichloromethane (DCM) was added 1 equiv. of
[RuCp(CH3CN)3]PF6. The reaction mixture was left stirring overnight at room
temperature. The reaction mixture was centrifuged, the supernatant was collected
and the solvent was removed under reduced pressure yielding the complex RuL1 as
a dark solid (65%).
Cell culture experiments. All cell lines were cultured in DMEM supplemented
with 10% (v/v) FBS, 5 mM glutamine, penicillin (100 U ml 1) and streptomycin
(100 U ml 1; all from Invitrogen). Proliferating cell cultures were maintained
in a 5% CO2 humidified incubator at 37 C. Unless otherwise specified, all
incubations were performed in DMEM supplemented with 5% of FBS
(DMEM-FBS) at 37 C.
Viability assays. The toxicity of the catalysts Ru1 and RuL1–RuL3 was tested by
MTT assay in HeLa and A549 cell lines as follows: 15,000 cells per well were seeded
in 96-well plates 1 day before treatment with different concentrations of the
catalysts. After 24 h of incubation, medium containing Thiazolyl Blue Tetrazolium
Bromide (Sigma) was added to a final concentration of 0.5 mg ml 1. Cells were
then incubated for 4 h to allow the formation of formazan precipitates by
metabolically active cells. A detergent solution of 10% SDS and 0.01 M HCl was
then added and the plate was incubated overnight at room temperature to allow
the solubilization of the precipitates. The quantity of formazan in each well
(directly proportional to the number of viable cells) was measured by recording
changes in absorbance at 570 nm in a microtitre plate reading spectrophotometer
(Tecan Infinite 200 PRO).
Catalytic experiments in living cells. Uncaging of Rho-alloc. Cells growing on
glass coverslips were incubated with either catalyst Ru1, RuL1, RuL2 or RuL3
(50 mM) and TMRE (100 nM) for 30 min. Cells were then washed twice with
DMEM-FBS and incubated with Rho-alloc (100 mM) for 30 min. Before observa-
tion by fluorescence microscopy, the samples were washed twice with fresh
DMEM-FBS. The coverslips were observed in vivo in a fluorescence microscope
equipped with adequate filters. Digital pictures of the different samples were taken
under identical conditions of gain and exposure.
Uncaging of DNP-allyl. Cells growing on glass coverslips were incubated with
either catalyst RuL2 or RuL3 (50 mM) for 30 min. Cells were then washed twice
with DMEM-FBS and incubated with the caged DNP-allyl (500 mM) for 30 min.
Finally, TMRE (100 nM) was added to the incubation medium for 10 min. The
coverslips were then observed in vivo in a fluorescence microscope equipped with
adequate filters. Digital pictures of the different samples were taken under identical
conditions of gain and exposure.
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its Supplementary Information files. Other
data that support the findings of this study are available from the corresponding
author on request.
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